Sylvester Comprehensive Cancer Center (Main)

University of Miami Health System

Miami, FL

Sorting 12 by

Accepting patients

OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

BMT CTN 2203

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
  • JAK1 Inhibitor
  • JAK2 Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Post-Allogeneic Stem Cell Transplant
  • Randomization
  • Phase 3

Accepting patients

KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
  • Growth Factor
  • Phase 2
  • Has results

Accepting patients

R289

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
  • IRAK 1 Inhibitor
  • IRAK 4 Inhibitor
  • Phase 1/2

Accepting patients

NEROFE

An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
  • Phase 1

Not currently accepting

Luspatercept and Lenalidomide (L2)

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
  • Erythroid Maturation Agent (EMA)
  • Immunomodulatory Drug
  • Red Blood Cell Stimulant
  • Phase 1/2

Not yet accepting

AZTOUND

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
  • DNMT1 Inhibitor
  • Phase 2/3

Accepting patients

LIMBER

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
  • BET Inhibitor
  • JAK1 Inhibitor
  • JAK2 Inhibitor
  • Phase 1

Accepting patients

SX-682

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1
  • Has results